Inflammatory Mediators in Early Sepsis

• Conditions: Inflammation

• Registration Number: NCT02692118
• Lead Sponsor: University Hospital Tuebingen

Brief Summary

Sepsis is still a challenge for clinicians since the detailed pathomechanism are still unknown and until now early markers for sepsis are not defined yet. Immunological pathways and new mediators defined in animal models are not yet investigated in patients with sepsis. Therefore the investigators will measure new mediators in patients with septic shock.

Detailed Description

Semaphorins 1 to 7 will be determined in Blood of patients with early septic shock. Concentration will be compared with blood concentration of postoperative patients suffering systemic inflammatory response syndrome (SIRS).

Study Timeline

• Study First Submitted: 2016-02-22
• Study First Submitted QC: 2016-02-22
• Study First Posted: 2016-02-25
• Study Start: 2016-12
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-04
• Last Update Posted: 2021-06-07
• Primary Completion: 2022-06
• Study Completion: 2022-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Septic Shock

Exclusion Criteria

• Age < 18 > 85
• no consent of caregiver
• Trauma patients
• Burn patients
• Immunosuppression
• Pregnancy
• HIV- hepatitis infection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Semaphorin 1 to 7 in plasma of septic patients	12 months	Concentration of Semaphorin in plasma of 60 sepsis patients \[pg/ml\].

Trial Locations

Locations (1)

University Hospital Tuebingen; 🇩🇪 Tuebingen, Germany